Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GUTSNYSE:INFUNASDAQ:OBIOOTCMKTS:PEYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGUTSFractyl Health$2.06-5.1%$1.61$0.87▼$5.74$100.89M1.85326,270 shs290,851 shsINFUInfuSystem$6.21+1.8%$5.39$4.61▼$9.97$130.51M1.8198,896 shs129,455 shsOBIOOrchestra BioMed$3.09-2.2%$2.87$2.37▼$8.87$118.39M0.64170,746 shs154,024 shsPEYEPrecision Optics$0.00$1.61▼$2.69$32.98M0.419,793 shs113,500 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGUTSFractyl Health0.00%+3.52%+21.89%+62.20%-63.48%INFUInfuSystem0.00%+1.64%+0.98%+8.00%-13.03%OBIOOrchestra BioMed0.00%-6.65%+6.55%-24.82%-61.23%PEYEPrecision Optics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGUTSFractyl Health2.2955 of 5 stars3.52.00.00.03.50.00.0INFUInfuSystem2.746 of 5 stars2.03.00.00.02.44.21.9OBIOOrchestra BioMed3.0505 of 5 stars4.63.00.00.02.70.80.0PEYEPrecision OpticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGUTSFractyl Health 3.00Buy$11.00433.98% UpsideINFUInfuSystem 4.00Strong Buy$13.00109.34% UpsideOBIOOrchestra BioMed 3.20Buy$14.20359.55% UpsidePEYEPrecision Optics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PEYE, INFU, OBIO, and GUTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/5/2025OBIOOrchestra BioMedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $12.004/23/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/22/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/15/2025GUTSFractyl HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/4/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.004/3/2025OBIOOrchestra BioMedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/1/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/20/2025OBIOOrchestra BioMedBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.003/18/2025INFUInfuSystemSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGUTSFractyl Health$60K1,681.54N/AN/AN/A∞INFUInfuSystem$137.58M0.95$0.49 per share12.79$2.47 per share2.51OBIOOrchestra BioMed$2.89M41.02N/AN/A$1.90 per share1.63PEYEPrecision Optics$15.68M0.00N/AN/A$0.53 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGUTSFractyl Health-$77.09M-$1.85N/AN/AN/A-64,849.48%N/A-57.21%8/13/2025 (Estimated)INFUInfuSystem$870K$0.14103.5220.03N/A1.12%2.78%1.41%N/AOBIOOrchestra BioMed-$49.12M-$1.78N/AN/AN/A-2,179.33%-107.04%-70.88%N/APEYEPrecision Optics-$930K-$0.06N/AN/AN/A-5.93%-12.10%-6.41%N/ALatest PEYE, INFU, OBIO, and GUTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025GUTSFractyl Health-$0.49-$0.49N/A-$0.49N/AN/A5/12/2025Q1 2025OBIOOrchestra BioMed-$0.46-$0.49-$0.03-$0.49$0.39 million$0.87 million3/31/2025Q4 2024OBIOOrchestra BioMed-$0.43-$0.43N/A-$0.43$0.79 million$0.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGUTSFractyl HealthN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/APEYEPrecision OpticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGUTSFractyl Health0.605.585.57INFUInfuSystem0.501.981.59OBIOOrchestra BioMedN/A4.234.21PEYEPrecision Optics0.231.420.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGUTSFractyl HealthN/AINFUInfuSystem71.13%OBIOOrchestra BioMed53.55%PEYEPrecision OpticsN/AInsider OwnershipCompanyInsider OwnershipGUTSFractyl HealthN/AINFUInfuSystem11.40%OBIOOrchestra BioMed8.10%PEYEPrecision Optics22.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGUTSFractyl Health10248.98 millionN/AN/AINFUInfuSystem41021.02 million19.10 millionOptionableOBIOOrchestra BioMed438.31 million35.47 millionNot OptionablePEYEPrecision Optics8016.92 million13.08 millionNot OptionablePEYE, INFU, OBIO, and GUTS HeadlinesRecent News About These CompaniesLaCroix Precision Optics Expanding Manufacturing Operations in BatesvilleJune 9, 2025 | armoneyandpolitics.comTag: LaCroix Precision OpticsJune 6, 2025 | talkbusiness.netLaCroix Precision Optics expanding in Batesville, adding 107 jobsJune 6, 2025 | talkbusiness.netLaCroix Precision Optics announces $13.8M expansion, creating 107 jobs in BatesvilleJune 6, 2025 | msn.comPrecision Optics Corporation Third Quarter 2025 Earnings: US$0.30 loss per share (vs US$0.052 loss in 3Q 2024)May 17, 2025 | uk.finance.yahoo.comPrecision Optics Corporation, Inc. (NASDAQ:POCI) Q3 2025 Earnings Call TranscriptMay 17, 2025 | msn.comQ3 2025 Precision Optics Corporation Inc Earnings CallMay 16, 2025 | uk.finance.yahoo.comPrecision Optics Enters into Main Purchase Agreement with Top Tier Aerospace Customer and Expands Program Backlog to $6.6 MillionApril 3, 2025 | manilatimes.netPrecision Optics appoints Joseph Pellegrino to board of directorsMarch 21, 2025 | markets.businessinsider.comRochester Precision Optics looks global with $50M funding commitmentMarch 5, 2025 | optics.orgPrecision Optics Corporation, Inc. (NASDAQ:POCI) Q2 2025 Earnings Call TranscriptFebruary 17, 2025 | msn.comPrecision Optics Corporation Second Quarter 2025 Earnings: US$0.15 loss per share (vs US$0.13 loss in 2Q 2024)February 15, 2025 | finance.yahoo.comPrecision Optics Corporation: Precision Optics Reports Second Quarter Fiscal Year 2025 Financial ResultsFebruary 15, 2025 | finanznachrichten.dePrecision Optics Corporation, Inc. (POCI) Q2 2025 Earnings Call TranscriptFebruary 14, 2025 | seekingalpha.comQ2 2025 Precision Optics Corporation Inc Earnings CallFebruary 14, 2025 | finance.yahoo.comPrecision Optics launches endoscopic platformJanuary 28, 2025 | msn.comPrecision Optics Corporation And 2 More Promising US Penny StocksNovember 13, 2024 | finance.yahoo.comNew Spectral Camera Uses AI to Boost Farm Yields by 20%November 6, 2024 | msn.comMicro Eyewear Inc.: Making Eyeglasses That Bring Clarity to See Future OpportunitiesNovember 5, 2024 | msn.comTiny eye movements are the key to making your vision sharperOctober 30, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsToyota Supercharges Joby: $250M Capital Infusion Ignites Stock By Jeffrey Neal Johnson | May 28, 2025View Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock PEYE, INFU, OBIO, and GUTS Company DescriptionsFractyl Health NASDAQ:GUTS$2.06 -0.11 (-5.07%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.11 +0.05 (+2.43%) As of 05:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.InfuSystem NYSE:INFU$6.21 +0.11 (+1.80%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.16 -0.05 (-0.81%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Orchestra BioMed NASDAQ:OBIO$3.09 -0.07 (-2.22%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.14 +0.05 (+1.62%) As of 05:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Precision Optics OTCMKTS:PEYEPrecision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
